In this view, Cortazar and colleagues [53] identified three different risk factors for AKI development: concomitant use of PPI [58], lower glomerular filtration rate at baseline and concomitant use of anti-PD1 and anti-CTLA4 drugs. The gene discussed is CTLA4; the disease is acute kidney injury.